Nuvation Bio Inc (NUVB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nuvation Bio Inc (NUVB) has a cash flow conversion efficiency ratio of -0.162x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.89 Million) by net assets ($325.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nuvation Bio Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Nuvation Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Nuvation Bio Inc for a breakdown of total debt and financial obligations.
Nuvation Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nuvation Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Montea C.V.A.
BR:MONT
|
0.008x |
|
Chengdu CORPRO Technology Co Ltd
SHE:300101
|
0.008x |
|
BitVentures Limited
NASDAQ:BVC
|
N/A |
|
Shandong Gettop Acoustic Co Ltd
SHE:002655
|
-0.031x |
|
1st Source Corporation
NASDAQ:SRCE
|
0.039x |
|
Tecan Group AG
SW:TECN
|
0.048x |
|
Dianguang Explosion-proof Technology Co Ltd
SHE:002730
|
-0.020x |
|
American Superconductor Corporation
NASDAQ:AMSC
|
0.006x |
Annual Cash Flow Conversion Efficiency for Nuvation Bio Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Nuvation Bio Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Nuvation Bio Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $463.79 Million | $-130.41 Million | -0.281x | -150.23% |
| 2023-12-31 | $605.12 Million | $-68.00 Million | -0.112x | +23.41% |
| 2022-12-31 | $655.08 Million | $-96.11 Million | -0.147x | -60.50% |
| 2021-12-31 | $746.00 Million | $-68.19 Million | -0.091x | +46.18% |
| 2020-12-31 | $215.08 Million | $-36.53 Million | -0.170x | +18.15% |
| 2019-12-31 | $117.75 Million | $-24.43 Million | -0.207x | -125.06% |
| 2018-12-31 | $-744.00K | $-616.00K | 0.828x | -- |
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug c… Read more